GSK Singapore announces availability of Shingrix in Singapore for shingles prevention
SINGAPORE, Jan. 10, 2022 /PRNewswire/ -- GlaxoSmithKline (GSK) Singapore announced that a new vaccine to help protect against shingles, Shingrix, is now available in Singapore. Shingrix is a non-live, recombinant subunit adjuvanted vaccine, given intramuscularly in two doses, for the prevention of shingles (herpes zoster). The vaccine was initially approved for adults aged 50 years and over, with the...
Source: asiaone.com